Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Fortress Biotech Inc FBIO

Alternate Symbol(s):  FBIOP

Healthcare Biotechnology
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. The Company markets its various branded dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Ximino, Exelderm and Targadox. Qbrexza (glycopyrronium 2.4%) is a medicated cloth towelette for the treatment of primary axillary... see more

Recent & Breaking News (NDAQ:FBIO)

Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference

GlobeNewswire October 5, 2023

Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds

GlobeNewswire October 2, 2023

Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference

GlobeNewswire September 21, 2023

Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 7, 2023

Mustang Bio to Participate in Upcoming September 2023 Investor Conferences

GlobeNewswire September 7, 2023

Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 6, 2023

Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian Nations

GlobeNewswire September 6, 2023

Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 5, 2023

Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

GlobeNewswire August 16, 2023

Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2023

Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2023

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2023

Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire August 10, 2023

Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire August 8, 2023

Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023

GlobeNewswire August 3, 2023

Mustang Bio to Participate in Two August 2023 Investor Conferences

GlobeNewswire August 3, 2023

Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023

GlobeNewswire August 2, 2023

Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study

GlobeNewswire August 1, 2023

Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences

GlobeNewswire July 31, 2023

Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market

GlobeNewswire July 31, 2023